The global antisense oligonucleotides market is projected to amass revenue of around US$ 5,519.6 million by 2033, up from US$ 2,913.5 million in 2023 moving forward with a CAGR of 6.6% during the forecast period.
The antisense oligonucleotides adoption trends are significantly swayed by their promising treatment options for a range of medical disorders. Moreover, they also facilitate the development of therapeutics affecting protein targets that cannot be treated with protein therapeutics, propelling the market growth. They target a particular malfunctioning gene, interfere with RNA function at the cellular level, and also be silenced or modulated and the same is catching the attention of market players.
The rising demand for antisense oligonucleotides is attributed to its aid in modifying the immune system that facilitates the treatment of a wide range of autoimmune disorders - that cannot be treated with available drugs.
It is easy to scale up the commercial scale GMP production of these oligonucleotides compared to other biologic therapies, spurring the adoption of antisense oligonucleotides.
Moreover, the market is enhanced by the minimal side effects of antisense oligonucleotides, which are controlled with ease as compared to other classes of drugs.
The antisense oligonucleotides sector has witnessed four FDA approvals [fomivirsen (Vitravene) approved in 1998 - which was discontinued due to low demand; pegaptanib (Macugen) in 2004; mipomersen (Kynamro) in 2013; and eteplirsen (Exondys 51) in 2016).
However, this market is yet to achieve recognition as a valuable drug category like biologics, small molecules, and gene and cell therapy.
However, this was projected to change with the approval of nusinersen (Spinraza) for treating spinal muscular atrophy (SMA), which is one of the most common genetic causes of infant mortality with no approved treatments.
Even when the market performance of antisense oligonucleotides is not predictable as like other segments of the industry, the market outlook is positively influenced by the leading players in the market and the amount of research and development investments.
Attributes | Details |
---|---|
Antisense Oligonucleotides Market CAGR (2023 to 2033) | 6.6% |
Antisense Oligonucleotides Market Size (2023) | US$ 2,913.5 million |
Antisense Oligonucleotides Market Size (2033) | US$ 5,519.6 million |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
A strong pipeline of antisense oligonucleotides and increased focus on a large number of product approvals and commercialization are likely to expand the global antisense oligonucleotides sector size.
Moreover, significant advances in the field of antisense oligonucleotides at a therapeutic or clinical level are further contributing to the growth of the global market.
However, the global antisense oligonucleotides business is grappling with numerous challenges related to the diversity of oligonucleotides, delivery, and regulatory complexity.
Despite several advancements at clinical levels, the delivery of active oligonucleotides to the actual site within target cells is still one of the key challenges hindering the growth of the global antisense oligonucleotides sector. In addition to this, developing a new set of unique regulatory guidelines is also expected to hamper the market statistics.
Countries | Market Share (2022) |
---|---|
United States | 58% |
Germany | 3.3% |
Japan | 2.9% |
North America clearly dominates the global antisense oligonucleotides industry due to a strong product pipeline and an increasing number of FDA approvals in the region, contributing to the region’s market share of 60.9% in 2022.
For instance, the international biotechnology company Biogen Inc.'s Nusinersen, sold as Spinraza, received FDA approval in the USA in 2018. Health infrastructures and an increase in the use of oligonucleotides in the development of innovative pharmacological therapies are additional factors driving market expansion.
In 2022, the Europe antisense oligonucleotides sector captured a share of 14.3%. In order to improve their product portfolio for antisense oligonucleotides, key players in Europe are concentrating on strategic mergers and acquisitions, in turn spurring the market growth in Europe.
For instance, in 2014, the multinational pharmaceutical and biopharmaceutical company AstraZeneca Plc. merged with the pharmaceutical firm Ionis Pharmaceuticals. Additionally, it is anticipated that a strong pipeline of important companies aids the market growth to some level.
While many organizations are working on RNA-based treatments and vaccines, including well-known companies like Pfizer, BioNtech, Moderna, etc., a few biotech start-ups are also emerging, shaping the market trends.
Examples:
The company's tiny molecule medications bind to targets that were previously believed to be unreachable as well as those that were confirmed using genetic and pharmacological techniques.
These medications use multiple ways to either decrease RNA translation or splicing. Drugs for oncology, dyslipidemia, and uncommon disorders are in the startup's development.
The company's top therapeutic candidate for type 1 myotonic dystrophy is an anti-microRNA (DM1). The start-up's anti-miRs are shown to suppress microRNAs that repress MBNL1/2 genes in DM1 in muscle biopsies of patients.
The market for antisense oligonucleotides is fairly consolidated, with a few competitors gaining a significant growing share. The market participants for antisense oligonucleotides are heavily invested in research and development. These activities assist the participants in developing novel formulations that are advantageous to the user.
A couple of recent developments are:
The agreement improves MilliporeSigma's capacity to produce and develop mRNA for its clients' usage in Covid-19 and numerous other diseases-related vaccines, therapies, and diagnostics.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Robust product pipeline and rising FDA approvals in the region dominate the market.
The rising number of FDA approvals is the key opportunity in the market.
Advanced pharmacological techniques are the key trend.
Promising treatment offers for medical disorders.
The market is forecast to register a CAGR of 6.6% through 2033.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug, 2023 to 2033 5.3.1. Approved Drugs 5.3.2. Pegaptanib 5.3.3. Mipomersen 5.3.4. Eteplirsen 5.3.5. Pipeline Analysis 5.4. Y-o-Y Growth Trend Analysis By Drug, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Indication, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication, 2023 to 2033 6.3.1. Ocular Diseases 6.3.2. Cancer 6.3.3. Diabetes 6.3.4. Amyotrophic Lateral Sclerosis (ALS) 6.3.5. Duchenne Muscular Dystrophy 6.3.6. Spinal Muscular Atrophy 6.3.7. Others 6.4. Y-o-Y Growth Trend Analysis By Indication, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Indication, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Application , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application , 2023 to 2033 7.3.1. Basic Research 7.3.2. Genomics 7.3.3. Target Validation 7.3.4. Drug Discovery 7.4. Y-o-Y Growth Trend Analysis By Application , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Application , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Western Europe 8.3.4. Eastern Europe 8.3.5. South Asia and Pacific 8.3.6. East Asia 8.3.7. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA. 9.2.1.2. Canada 9.2.2. By Drug 9.2.3. By Indication 9.2.4. By Application 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug 9.3.3. By Indication 9.3.4. By Application 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Drug 10.2.3. By Indication 10.2.4. By Application 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug 10.3.3. By Indication 10.3.4. By Application 10.4. Key Takeaways 11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United Kingdom. 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Western Europe 11.2.2. By Drug 11.2.3. By Indication 11.2.4. By Application 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug 11.3.3. By Indication 11.3.4. By Application 11.4. Key Takeaways 12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Poland 12.2.1.2. Russia 12.2.1.3. Czech Republic 12.2.1.4. Romania 12.2.1.5. Rest of Eastern Europe 12.2.2. By Drug 12.2.3. By Indication 12.2.4. By Application 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug 12.3.3. By Indication 12.3.4. By Application 12.4. Key Takeaways 13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Bangladesh 13.2.1.3. Australia 13.2.1.4. New Zealand 13.2.1.5. Rest of South Asia and Pacific 13.2.2. By Drug 13.2.3. By Indication 13.2.4. By Application 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug 13.3.3. By Indication 13.3.4. By Application 13.4. Key Takeaways 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Drug 14.2.3. By Indication 14.2.4. By Application 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug 14.3.3. By Indication 14.3.4. By Application 14.4. Key Takeaways 15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Drug 15.2.3. By Indication 15.2.4. By Application 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug 15.3.3. By Indication 15.3.4. By Application 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA. 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Drug 16.1.2.2. By Indication 16.1.2.3. By Application 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Drug 16.2.2.2. By Indication 16.2.2.3. By Application 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Drug 16.3.2.2. By Indication 16.3.2.3. By Application 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Drug 16.4.2.2. By Indication 16.4.2.3. By Application 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Drug 16.5.2.2. By Indication 16.5.2.3. By Application 16.6. United Kingdom. 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Drug 16.6.2.2. By Indication 16.6.2.3. By Application 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Drug 16.7.2.2. By Indication 16.7.2.3. By Application 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Drug 16.8.2.2. By Indication 16.8.2.3. By Application 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Drug 16.9.2.2. By Indication 16.9.2.3. By Application 16.10. Poland 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Drug 16.10.2.2. By Indication 16.10.2.3. By Application 16.11. Russia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Drug 16.11.2.2. By Indication 16.11.2.3. By Application 16.12. Czech Republic 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Drug 16.12.2.2. By Indication 16.12.2.3. By Application 16.13. Romania 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Drug 16.13.2.2. By Indication 16.13.2.3. By Application 16.14. India 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Drug 16.14.2.2. By Indication 16.14.2.3. By Application 16.15. Bangladesh 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Drug 16.15.2.2. By Indication 16.15.2.3. By Application 16.16. Australia 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Drug 16.16.2.2. By Indication 16.16.2.3. By Application 16.17. New Zealand 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Drug 16.17.2.2. By Indication 16.17.2.3. By Application 16.18. China 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Drug 16.18.2.2. By Indication 16.18.2.3. By Application 16.19. Japan 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Drug 16.19.2.2. By Indication 16.19.2.3. By Application 16.20. South Korea 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Drug 16.20.2.2. By Indication 16.20.2.3. By Application 16.21. GCC Countries 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Drug 16.21.2.2. By Indication 16.21.2.3. By Application 16.22. South Africa 16.22.1. Pricing Analysis 16.22.2. Market Share Analysis, 2022 16.22.2.1. By Drug 16.22.2.2. By Indication 16.22.2.3. By Application 16.23. Israel 16.23.1. Pricing Analysis 16.23.2. Market Share Analysis, 2022 16.23.2.1. By Drug 16.23.2.2. By Indication 16.23.2.3. By Application 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Drug 17.3.3. By Indication 17.3.4. By Application 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Ionis Pharmaceuticals, Inc. 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Sarepta Therapeutics 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Biogen 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Alnylam Pharmaceuticals, Inc. 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Antisense Therapeutics Limited 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Isarna Therapeutics GmbH 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Arrowhead Pharmaceuticals, Inc. 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Alantic Pharmaceuticals, Inc. 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Enzon Pharmaceuticals, Inc. 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Bio-Path Holdings, Inc. 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 18.1.11. Gene Signal International SA 18.1.11.1. Overview 18.1.11.2. Product Portfolio 18.1.11.3. Profitability by Market Segments 18.1.11.4. Sales Footprint 18.1.11.5. Strategy Overview 18.1.11.5.1. Marketing Strategy 18.1.12. GlaxoSmithKline plc 18.1.12.1. Overview 18.1.12.2. Product Portfolio 18.1.12.3. Profitability by Market Segments 18.1.12.4. Sales Footprint 18.1.12.5. Strategy Overview 18.1.12.5.1. Marketing Strategy 18.1.13. Geron Corporation 18.1.13.1. Overview 18.1.13.2. Product Portfolio 18.1.13.3. Profitability by Market Segments 18.1.13.4. Sales Footprint 18.1.13.5. Strategy Overview 18.1.13.5.1. Marketing Strategy 18.1.14. Grades 18.1.14.1. Overview 18.1.14.2. Product Portfolio 18.1.14.3. Profitability by Market Segments 18.1.14.4. Sales Footprint 18.1.14.5. Strategy Overview 18.1.14.5.1. Marketing Strategy 18.1.15. ICO Therapeutics 18.1.15.1. Overview 18.1.15.2. Product Portfolio 18.1.15.3. Profitability by Market Segments 18.1.15.4. Sales Footprint 18.1.15.5. Strategy Overview 18.1.15.5.1. Marketing Strategy 18.1.16. Aptose Biosciences 18.1.16.1. Overview 18.1.16.2. Product Portfolio 18.1.16.3. Profitability by Market Segments 18.1.16.4. Sales Footprint 18.1.16.5. Strategy Overview 18.1.16.5.1. Marketing Strategy 18.1.17. Marina Biotech 18.1.17.1. Overview 18.1.17.2. Product Portfolio 18.1.17.3. Profitability by Market Segments 18.1.17.4. Sales Footprint 18.1.17.5. Strategy Overview 18.1.17.5.1. Marketing Strategy 18.1.18. miRagen Therapeutics, Inc. 18.1.18.1. Overview 18.1.18.2. Product Portfolio 18.1.18.3. Profitability by Market Segments 18.1.18.4. Sales Footprint 18.1.18.5. Strategy Overview 18.1.18.5.1. Marketing Strategy 18.1.19. Synlogic, Inc. 18.1.19.1. Overview 18.1.19.2. Product Portfolio 18.1.19.3. Profitability by Market Segments 18.1.19.4. Sales Footprint 18.1.19.5. Strategy Overview 18.1.19.5.1. Marketing Strategy 18.1.20. OncoGenex Pharmaceuticals Inc. 18.1.20.1. Overview 18.1.20.2. Product Portfolio 18.1.20.3. Profitability by Market Segments 18.1.20.4. Sales Footprint 18.1.20.5. Strategy Overview 18.1.20.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports